Revolutionary CAR-T shot could free Graves' patients from lifelong pills
NCT ID NCT07333677
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This early-phase study tests a new treatment called HN2301 for people with refractory Graves' disease, a thyroid condition that doesn't get better with standard medication. HN2301 uses a special injection to turn the body's own immune cells into cancer-fighting-like cells that target the faulty immune response. Five participants will receive several doses and be monitored for safety and whether they can achieve remission without needing thyroid medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.